Previous 10 | Next 10 |
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties PR Newswire DALLAS , March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using i...
Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report® PR Newswire DALLAS , March 12, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ...
Lantern Pharma Inc. (LTRN) Q4 2020 Earnings Conference Call March 10, 2021 04:00 PM ET Company Participants Marek Ciszewski - Director, IR Panna Sharma - President and CEO David Margrave - CFO Conference Call Participants Kyle Bauser - Colliers Securities Daniel Carlson - TW Research Group Jo...
The following slide deck was published by Lantern Pharma Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Lantern Pharma Inc. 2020 Q4 - Results - Earnings Call Presentation
Lantern Pharma (LTRN): Q4 GAAP EPS of -$0.47 misses by $0.02.Cash and cash equivalents were $19.2 million as of December 31, 2020, compared to $20.8 million as of September 30, 2020 and $1.2 million as of December 31, 2019.Strengthened balance sheet following January 2021 public offering of $...
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights - RADR® artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints - Advanced opportunities for LP-184 in glioblastoma, prostate and pancreatic cancers i...
Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET PR Newswire DALLAS , March 3, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutic...
There is growing demand for AI use in drug development. Drug development deals go from $5 million to over $1 billion. Predictive Oncology has a unique platform using real patient samples in its AI process. Predictive Oncology could be undervalued if it can ink large or multipl...
Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option PR Newswire DALLAS , Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its pro...
Lantern Pharma (LTRN) has priced its public offering of 4,285,715 common shares at $14.00/share, for gross proceeds of $60M.Underwriters' over-allotment is an additional 642,856 shares. ThinkEquity is acting as sole book-running manager and Colliers Securities is as co-manager for the offerin...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...